{
    "table_id": "finqa_2ce3951a56",
    "source": "finqa",
    "original_metadata": {
        "source_dataset": "finqa",
        "document_id": "VRTX/2006/page_121.pdf-1",
        "pre_text_caption_evidence": [
            "vertex pharmaceuticals incorporated notes to consolidated financial statements ( continued ) o .",
            "significant revenue arrangements ( continued ) $ 7 million of development and commercialization milestone payments .",
            "additionally , kissei agreed to reimburse the company for certain development costs , including a portion of costs for phase 2 trials of vx-702 .",
            "research funding ended under this program in june 2000 , and the company has received the full amount of research funding specified under the agreement .",
            "kissei has exclusive rights to develop and commercialize vx-702 in japan and certain far east countries and co-exclusive rights in china , taiwan and south korea .",
            "the company retains exclusive marketing rights outside the far east and co-exclusive rights in china , taiwan and south korea .",
            "in addition , the company will have the right to supply bulk drug material to kissei for sale in its territory and will receive royalties or drug supply payments on future product sales , if any .",
            "in 2006 , 2005 and 2004 , approximately $ 6.4 million , $ 7.3 million and $ 3.5 million , respectively , was recognized as revenue under this agreement .",
            "the $ 7.3 million of revenue recognized in 2005 includes a $ 2.5 million milestone paid upon kissei 2019s completion of regulatory filings in preparation for phase 1 clinical development of vx-702 in japan .",
            "p .",
            "employee benefits the company has a 401 ( k ) retirement plan ( the 201cvertex 401 ( k ) plan 201d ) in which substantially all of its permanent employees are eligible to participate .",
            "participants may contribute up to 60% ( 60 % ) of their annual compensation to the vertex 401 ( k ) plan , subject to statutory limitations .",
            "the company may declare discretionary matching contributions to the vertex 401 ( k ) plan that are payable in the form of vertex common stock .",
            "the match is paid in the form of fully vested interests in a vertex common stock fund .",
            "employees have the ability to transfer funds from the company stock fund as they choose .",
            "the company declared matching contributions to the vertex 401 ( k ) plan as follows ( in thousands ) : q .",
            "related party transactions as of december 31 , 2006 , 2005 and 2004 , the company had a loan outstanding to a former officer of the company in the amount of $ 36000 , $ 36000 , $ 97000 , respectively , which was initially advanced in april 2002 .",
            "the loan balance is included in other assets on the consolidated balance sheets .",
            "in 2001 , the company entered into a four year consulting agreement with a director of the company for the provision of part-time consulting services over a period of four years , at the rate of $ 80000 per year commencing in january 2002 .",
            "the consulting agreement terminated in january 2006 .",
            "r .",
            "contingencies the company has certain contingent liabilities that arise in the ordinary course of its business activities .",
            "the company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. ."
        ],
        "question": "what was the percent change in revenue recognized under the agreement between 2004and 2005?"
    },
    "dimensions": {
        "rows": 3,
        "columns": 4
    },
    "schema": {
        "columns": [
            "",
            "2006",
            "2005",
            "2004"
        ],
        "dtypes": {
            "": "object",
            "2006": "object",
            "2005": "object",
            "2004": "object"
        }
    }
}